1 |
European Association for the Study of the Liver.EASL clinical practice guidelines: Management of chronic hepatitis B virus infection[J]. J Hepatol, 2017, 57(1): 167-185.
|
2 |
Schweitzer A, Horn J, Mikolajczyk RT, et al.Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013[J]. Lancet, 2015, 386(10003): 1546-1555.
|
3 |
Lozano R, Naghavi M, Foreman K, et al.Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2012, 380(9859): 2095-2128.
|
4 |
Ott JJ, Stevens GA, Groeger J, et al.Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity[J]. Vaccine, 2012, 30(12): 2212-2219.
|
5 |
Zarski JP, Marcellin P, Leroy V, et al.Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases[J]. J Hepatol, 2006, 45(3): 355-360.
|
6 |
Liaw YF.Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy[J]. Antivir Ther, 2006, 11(6): 669-679.
|
7 |
Di Marco V, Marzano A, Lampertico P, et al.Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine[J]. Hepatology, 2004, 40(4): 883-891.
|
8 |
Papatheodoridis GV, Dimou E, Dimakopoulos K, et al.Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine[J]. Hepatology, 2005, 42(1): 121-129.
|
9 |
Liaw YF, Kao JH, Piratvisuth T, et al.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update[J]. Hepatol Int, 2012, 6(3): 531-561.
|
10 |
Keeffe EB, Dieterich DT, Han SH, et al.A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update[J]. Clin Gastroenterol Hepatol, 2008, 6(12): 1315-1341.
|
11 |
Gordon SC, Liu Y, Miller MD, et al.No Detectable Resistance to Tenofovir Disoproxil Fumarate(TDF)Following up to 240 Weeks of Treatment in Patients with HBeAg+ and HBeAg-Chronic Hepatitis B Virus Infection[C]. Taipei: 22nd Conference of the Asian Pacific Association for the Study of the Liver(APASL), 2011.
|
12 |
Snow-Lampart A, Chappell B, Curtis M, et al.No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus[J]. Hepatology, 2011, 53(3): 763-773.
|
13 |
Tenney DJ, Rose RE, Baldick CJ, et al.Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy[J]. Hepatology, 2009, 49(5): 1503-1514.
|
14 |
Manns MP, Akarca US, Chang TT, et al.Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901[J]. Expert Opin Drug Saf, 2012, 11(3): 361-368.
|
15 |
Marcellin P, Gane E, Buti M, et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study[J]. Lancet, 2013, 381(9865): 468-475.
|
16 |
World Health Organization.Guidelines for the prevention, care and treatment of persons with chronic Hepatitis B infection[R]. Geneva: WHO, 2015.
|